Alexander von Humboldt Foundation

Biogen Appoints Jane Grogan as Head of Research

Retrieved on: 
Wednesday, September 6, 2023
Alexander von Humboldt Foundation, Business development, Drug development, RA, University, IBD, Head, EVP, Gene editing, BIIB, Drug, Genentech, Doctor of Philosophy, MS, Alexander von Humboldt, Immunity, Biology, Lupus, Leiden University, Autoimmunity, Rheumatoid arthritis, Pharmaceutical industry, Science, Biogen, Cancer, Immunology, Research

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023.
  • Dr. Grogan will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer.
  • Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies.
  • At Genentech, Dr. Grogan also integrated strategy between Early Discovery Research, Clinical Development, and Business Development and was project leader for engineered T cell therapies.

Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health

Retrieved on: 
Monday, September 12, 2022
Risk, Health, Therapy, Agriculture, Alexander von Humboldt Foundation, Biological Technologies Office (DARPA), COVID-19, Gene editing, NYSE, Infection, Center, U.S. Securities and Exchange Commission, BTO, Alexander von Humboldt, ARPA, Computer, DARPA, Face, Acquisition, K-12, Soarin' Eagle, Synthetic biology, Program, Business, Forward-looking statement, Georgia Institute of Technology College of Computing, Cancer, Technology, BS, General manager, Doctor of Philosophy, Food, Ginkgo Bioworks, White House, Research, DNA, Biotechnology, COVID-19 testing, SEC, Business development, Disease, Biology, Management, Pharmaceutical industry, Biosecurity, Ginkgo

BOSTON, Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health ( ARPA-H ).

Key Points: 
  • BOSTON, Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health ( ARPA-H ).
  • Dr. Wegrzyn is currently the Vice President for Business Development at Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming.
  • ARPA-H was established in March 2022 to drive transformative health breakthroughs that cannot readily be accomplished through traditional research or commercial activity.
  • "Some of the problems we face every day - especially in health and disease - are so large they can seem insurmountable.